Alkermes plc. vs Halozyme Therapeutics
Alkermes plc. and Halozyme Therapeutics are similar in size: $1.48bn and $1.40bn of revenue in their latest fiscal years. Halozyme Therapeutics grew faster (37.6% against -5.2%). Halozyme Therapeutics kept more of each dollar of sales as profit: a net margin of 22.7% against 16.4%.
| Latest fiscal year | Alkermes plc.ALKS, 2025 | Halozyme TherapeuticsHALO, 2025 |
|---|---|---|
| Revenue | $1.48bn | $1.40bn |
| Revenue growth | -5.2% | 37.6% |
| Net income | $242m | $317m |
| Operating margin | 17.2% | — |
| Net margin | 16.4% | 22.7% |
| Return on equity | 14.7% | 153.6% |
| Free cash flow | $480m | $645m |
| Cash | $389m | $134m |
| Total debt | $0 | $2.18bn |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $342m |
| Employees | 2,050 | 423 |
| Market value | $7.84bn | $14.77bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | 63 (Moderate) | 71 (Strong) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 105 sales |